Why Semaglutide Leads FDA Approved Weight Loss Drugs in 2025
Understanding Semaglutide’s Dominance in FDA-Approved Weight Loss Therapeutics In the evolving landscape of obesity management, semaglutide has emerged as the foremost FDA-approved pharmacological agent driving significant weight loss outcomes in 2025. This glucagon-like peptide-1 (GLP-1) receptor agonist has redefined therapeutic benchmarks by integrating potent appetite suppression with metabolic modulation, positioning it ahead of competing drugs … Read more